TSX up after index logs fresh record high close
Investing.com - Guggenheim maintained its Buy rating and $92.00 price target on Dianthus Therapeutics (NASDAQ:DNTH), currently trading at $26.45 with a market cap of $837 million, as the company approaches a key clinical data readout. According to InvestingPro data, the company holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations.
The research firm cited the imminent Phase II MaGic trial results in generalized myasthenia gravis (gMG) as a significant catalyst for the stock, suggesting the data could be released as early as next Monday.
Guggenheim expressed a "high-conviction view" on this catalyst, describing it as an asymmetric opportunity with potential upside of 100% versus downside of 50%, based on its analysis.
The firm believes positive results would require a placebo-adjusted change of at least 1.8 points in the MG-ADL score, along with consistency across other efficacy measures and favorable safety data.
Dianthus Therapeutics remains one of Guggenheim’s "Top Picks," with the firm stating that the gMG opportunity appears largely discounted at the current stock price.
In other recent news, Dianthus Therapeutics has been in the spotlight as it gears up for the release of Phase 2 clinical trial results for its treatment targeting generalized myasthenia gravis (gMG). Analysts from Cantor Fitzgerald have maintained an Overweight rating on the company, citing it as a "Top Pick" in anticipation of the trial data expected in September 2025. Guggenheim has also reiterated its Buy rating for Dianthus, raising its price target from $84.00 to $92.00, while highlighting the stock as one of its "Top Picks for 2025." Stifel has echoed similar sentiments, maintaining a Buy rating and a $52.00 price target, noting the significance of the upcoming clinical readout. Meanwhile, The Oncology Institute has announced the appointment of Anne McGeorge as the new Chairman of the Board, effective August 12, 2025. McGeorge brings over 35 years of healthcare financial experience to the role, succeeding Richard Barasch following his retirement. These developments underscore significant shifts and expectations within both companies as they navigate their respective sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.